Advances in novel anti-OX40 cancer immunotherapy
10.3760/cma.j.issn.0254-5101.2017.03.014
- VernacularTitle:肿瘤免疫治疗新靶点OX40的研究进展
- Author:
Ping DU
;
Lihong LIU
- Keywords:
OX40;
Immune checkpoint;
Tumor;
Immunotherapy
- From:
Chinese Journal of Microbiology and Immunology
2017;37(3):240-244
- CountryChina
- Language:Chinese
-
Abstract:
OX40 (CD134) is a member of the tumor necrosis factor receptors and mainly expressed on the surface of active lymphocytes.Being an important pair of co-stimulatory factors in the process of immune response, OX40 and its ligand OX40L play an important role in inducing anti-tumor immune response.They regulate the immunosuppressive effect in tumor microenvironment and enhance the killing activities of effector cells.Pre-clinical animal studies have shown that agonists for OX40, whether they are used alone or in combination with other treatments, have stronger anti-tumor effects.Several anti-OX40 agonistic monoclonal antibodies (McAb) are currently tested in early phase cancer clinical trials.This review focuses on the advances in anti-OX40 mAbs-based therapy in terms of molecular and biological properties, mechanism of action, monotherapy and combined therapy.
